TrialFrontiers in immunology2023

Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study.

Amir I Tukhvatulin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.